RE: Hemogenyx Staff10 Jul 2025 19:30
Wonder if vlad is regretting declining the rumoured £800k for CDX now.
Looks like no funding or deal in sight for the next 6 months, but then those of us who have been with Avacta for many years will have known this, it's now about focus on one asset, minimising costs and getting as much data as possible to extract value.
For hemo to exist as a going concern, I think vlad will need to make some far more difficult decisions going forwards. I have no doubt in the science, but hemo do not have the resources, and while I think placings will keep things going for another 6 months which is fine by me, he will need to relent control and have hemo take a minority stake in car-t to see it over the line. I've mentioned before, I still think this has excellent potential to return £10-15 a share to shareholders in 2/3 years, even with future dilution, so I will not be selling. That would see many of us with a multiple ROI. Granted not the £100's a share equivalent some hoping for 2 or 3 years ago, but the investing landscape has changed and it's still a fantastic return imo. Now let's just get behind hemo and look out for some exciting milestones over the next 18 months.